Optic IconOptic Logo
|
SearchCollectionsBenchmarks
Indication

Bile Duct Cancer

94 clinical trials

123 products

21 drugs

Product
CT-0508
Clinical trial
A Multicenter Phase 2/3 Trial of the Efficacy and Safety of Intracerebroventricular Radioimmunotherapy Using 131I-omburtamab for Neuroblastoma Central Nervous System/Leptomeningeal Metastases
Status: Terminated, Estimated PCD: 2023-06-02
Product
Pembrolizumab
Clinical trial
A Phase Ib/II Study of TT-00420 Tablet, as Monotherapy or in Combination Regimens, to Evaluate the Safety, Tolerability, Pharmacokinetics and Efficacy in Patients With Advanced Solid Tumor
Status: Recruiting, Estimated PCD: 2024-09-01
Product
Atezolizumab
Product
MDX2001
Product
UCMYM802
Clinical trial
A Phase 1/2a, Multicenter, First-in-human, Open-label Clinical Trial Evaluating MDX2001 Monotherapy in Patients With Advanced Solid Tumors
Status: Not yet recruiting, Estimated PCD: 2028-08-01
Clinical trial
A First-In-Human, Single Arm, Open-label, Phase 1 Dose-Escalation Study of UCMYM802 Injection in Mesothelin-positive Advanced Malignant Solid Tumors
Status: Recruiting, Estimated PCD: 2025-03-01
Product
TT-00420
Clinical trial
Open-Label, Multicenter, Phase II/III Study of Combination Therapy of D07001-Softgel Capsules and Xeloda/TS-1 in Subjects With Advanced Biliary Tract Cancer After Gemcitabine and Cisplatin-Based Treatment Failure
Status: Recruiting, Estimated PCD: 2026-07-01
Product
mFOLFOX
Product
D07001
Product
LOAd703
Clinical trial
Phase I/II Trial Investigating an Immunostimulatory Oncolytic Adenovirus for Cancer
Status: Active (not recruiting), Estimated PCD: 2023-08-22
Product
Nab-Paclitaxel
Clinical trial
A Phase 1 Open-Label Study to Evaluate the Safety, Tolerability, Pharmacokinetics and Efficacy of BL-M07D1 in Subjects With HER2 Expressing Advanced Malignant Solid Tumors
Status: Recruiting, Estimated PCD: 2025-08-24
Product
D07001-softgel capsules
Product
BL-M07D1
Clinical trial
A Phase II Study to Evaluate the Safety and the Efficacy of GEN-001 in Combination With Pembrolizumab for Patients With Advanced Refractory Biliary Tract Cancer
Status: Recruiting, Estimated PCD: 2026-10-01
Clinical trial
My Pathway: An Open-Label Phase IIa Study Evaluating Trastuzumab/Pertuzumab, Erlotinib, Vemurafenib/Cobimetinib, Vismodegib, Alectinib, and Atezolizumab in Patients Who Have Advanced Solid Tumors With Mutations or Gene Expression Abnormalities Predictive of Response to One of These Agents
Status: Completed, Estimated PCD: 2023-05-24
Product
GEN-001
Product
Pertuzumab
Product
Erlotinib
Product
Vemurafenib
Product
Cobimetinib
Product
Vismodegib
Product
Alectinib
Clinical trial
A Phase IIIb, Single Arm, Open-label, Multicentre Study of Durvalumab in Combination With Chemotherapy for the First Line Treatment for Patients With Advanced Biliary Tract Cancers (TOURMALINE)
Status: Recruiting, Estimated PCD: 2025-09-17
Product
Gemcitabine + Oxaliplatin
Product
Durvalumab
Product
Gemcitabine
Product
Gemcitabine + Cisplatin
Product
Gemcitabine + Cisplatin + S-1
Product
Gemcitabine + Carboplatin
Product
Gemcitabine + S-1
Product
Gemcitabine + Cisplatin + Albumin-bound Paclitaxel
Product
ELI-002
Clinical trial
First in Human Phase 1 Trial of ELI-002 Immunotherapy as Treatment for Subjects With Kirsten Rat Sarcoma (KRAS) Mutated Pancreatic Ductal Adenocarcinoma and Other Solid Tumors
Status: Active (not recruiting), Estimated PCD: 2023-01-26
Product
ZW25
Product
D07001-softgel capsules + Xeloda (or TS-1)
Clinical trial
Phase 2 Study of ZW25 Plus First-line Combination Chemotherapy in HER2-Expressing Gastrointestinal (GI) Cancers, Including Gastroesophageal Adenocarcinoma (GEA), Biliary Tract Cancer (BTC), and Colorectal Cancer (CRC)
Status: Active (not recruiting), Estimated PCD: 2025-11-28
Product
Cisplatin
Product
Capecitabine
Product
Fluorouracil
Product
Leucovorin
Product
Bevacizumab
Product
Oxaliplatin
Clinical trial
A Phase 2a, Double-blind, Placebo-controlled, Multi-center, Randomized Study Evaluating LSTA1 When Added to Standard of Care (SoC) Versus Standard of Care Alone in Subjects With Advanced Solid Tumors (BOLSTER)
Status: Recruiting, Estimated PCD: 2025-12-01
Product
FOLFOX
Product
LSTA1
Product
Placebo
Product
pembrolizumab
Clinical trial
A Clinical Trial of Pembrolizumab (MK-3475) Evaluating Predictive Biomarkers in Subjects With Advanced Solid Tumors (KEYNOTE 158)
Status: Recruiting, Estimated PCD: 2027-05-04
Clinical trial
A Multicenter Open-label Phase 1/1b Study to Evaluate the Safety and Preliminary Efficacy of SO-C101 as Monotherapy and in Combination With Pembrolizumab in Patients With Selected Advanced/Metastatic Solid Tumors
Status: Active (not recruiting), Estimated PCD: 2024-08-01
Product
SO-C101
Clinical trial
A Phase II, Open-Label, Multi-Drug, Multi-Center, Master Protocol to Evaluate the Efficacy and Safety of Novel Immunomodulators as Monotherapy and in Combination With Anticancer Agents in Participants With Advanced Hepatobiliary Cancer (GEMINI-Hepatobiliary)
Status: Recruiting, Estimated PCD: 2025-11-26
Product
Volrustomig
Product
Lenvatinib
Product
Rilvegostomig
Product
Zanidatamab
Clinical trial
An Open-label Randomized Trial of the Efficacy and Safety of Zanidatamab With Standard-of-care Therapy Against Standard-of-care Therapy Alone for Advanced HER2-positive Biliary Tract Cancer
Status: Recruiting, Estimated PCD: 2028-07-01
Product
PF-06940434
Product
PF-06801591
Clinical trial
A PHASE 1 STUDY TO EVALUATE THE SAFETY, PHARMACOKINETICS, AND PHARMACODYNAMICS OF ESCALATING DOSES OF PF-06940434 IN PATIENTS WITH ADVANCED OR METASTATIC SOLID TUMORS
Status: Active (not recruiting), Estimated PCD: 2024-08-30
Clinical trial
A Phase III, Randomized, Double-Blind, Placebo-Controlled, Multicenter, Global Study of Rilvegostomig in Combination With Chemotherapy as Adjuvant Treatment After Resection of Biliary Tract Cancer With Curative Intent (ARTEMIDE-Biliary01)
Status: Recruiting, Estimated PCD: 2029-06-29
Product
Gemcitabine/Cisplatin
Product
S-1
Product
AZD5305
Clinical trial
A Modular Phase I/IIa, Open-label, Multicentre Study to Assess the Safety, Tolerability, Pharmacokinetics, Pharmacodynamics and Preliminary Efficacy of Ascending Doses of AZD5305 as Monotherapy and in Combination With Anti-cancer Agents in Patients With Advanced Solid Malignancies
Status: Recruiting, Estimated PCD: 2026-12-15
Product
Paclitaxel
Product
Carboplatin
Product
T- Dxd
Product
Camizestrant
Product
Gemcitabine + Cisplatin + Albumin-bound paclitaxel
Product
Dato-DXd
Clinical trial
CRESTONE: A Phase 2 Study of Seribantumab in Adult Patients With Neuregulin-1 (NRG1) Fusion Positive Locally Advanced or Metastatic Solid Tumors
Status: Active (not recruiting), Estimated PCD: 2025-01-01
Product
CTX-009
Clinical trial
A Phase 2/3 Randomized, Controlled Study of CTX-009 in Combination With Paclitaxel Versus Paclitaxel Alone in Adult Patients With Unresectable Advanced, Metastatic or Recurrent Biliary Tract Cancers Who Have Received One Prior Systemic Chemotherapy Regimen
Status: Recruiting, Estimated PCD: 2025-07-01
Clinical trial
Open-Label, Multicenter Study of D07001-Softgel Capsules (Oral Gemcitabine Hydrochloride) in Subjects With Unresectable, Metastatic or Locally Advanced Gastrointestinal (GI) Cancer in Dose-Escalation Phase and in Subjects With Advanced Biliary Tract Cancer (BTC) Following Primary Chemotherapy or Combined Chemoradiotherapy (CCRT) in Dose-Expansion Phase
Status: Completed, Estimated PCD: 2020-12-28
Product
STI-3031
Clinical trial
An Open-label, Multicenter, Global Phase 2 Basket Study to Investigate the Efficacy, Safety, Pharmacokinetics and Pharmacodynamics of STI-3031 in Patients With Selected Relapsed or Refractory Malignancies.
Status: Withdrawn, Estimated PCD: 2024-01-01
Clinical trial
Phase I Clinical Study of Chimeric Antigen Receptor T Cells (C-13-60) in the Treatment of Carcinoembryonic Antigen (CEA) Positive Advanced Malignant Solid Tumors
Status: Recruiting, Estimated PCD: 2026-12-31
Product
M7824
Clinical trial
A Phase II/III, Multicenter, Randomized, Placebo-controlled Study of Gemcitabine Plus Cisplatin With or Without Bintrafusp Alfa (M7824) as First-line Treatment of Biliary Tract Cancer
Status: Terminated, Estimated PCD: 2021-05-20
Clinical trial
A Phase 1 / 2 Study of CAN04, a Fully Humanized Monoclonal Antibody Against IL1RAP, in Combination With Different Chemotherapy Regimens in Subjects With Advanced Solid Tumours
Status: Completed, Estimated PCD: 2023-06-23
Product
Seribantumab
Product
DTX
Product
CEA-targeted CAR-T cells
Product
G/C
Product
CAN04
Clinical trial
Phase I/IIa, First-in-human, Open-label, Dose Escalation Trial With Expansion Cohorts to Evaluate Safety, Pharmacokinetics, Pharmacodynamics, and Preliminary Efficacy of BNT141 as a Monotherapy and in Combination With Other Anti-cancer Agents in Patients With CLDN18.2-positive Solid Tumors
Status: Terminated, Estimated PCD: 2023-07-24
Product
Nab-paclitaxel
Clinical trial
Randomized, Placebo-controlled, Open-label, Phase 2b Clinical Trial to Evaluate the Antitumor Activity of Combination Therapy of SMT-NK and Pembrolizumab vs Pembrolizumab Monotherapy in Patients With Advanced Biliary Tract Cancer
Status: Recruiting, Estimated PCD: 2025-01-08
Product
SMT-NK
Clinical trial
Safety, Pharmacokinetics (PK) and Efficacy of AI-061, A 1:1 Co-formulation of AI-025 (Anti-PD-1) and ONC-392 (Anti-CTLA-4) Antibodies in Advanced Solid Tumors: An Open-Label Phase 1 Study
Status: Recruiting, Estimated PCD: 2024-12-31
Product
BNT141
Product
AI-061
Clinical trial
A Phase II, Multicenter, Open-label Study to Investigate the Clinical Efficacy of M7824 Monotherapy in Participants With Locally Advanced or Metastatic Biliary Tract Cancer Who Fail or Are Intolerant to First-line Platinum-Based Chemotherapy
Status: Completed, Estimated PCD: 2020-11-09
Product
RAIN-32
Clinical trial
A Phase 2 Basket Study of Milademetan in Advanced/Metastatic Solid Tumors (MANTRA-2)
Status: Terminated, Estimated PCD: 2023-10-15
Clinical trial
A Phase I-II, FIH Study of A166 in Locally Advanced/Metastatic Solid Tumors Expressing Human Epidermal Growth Factor Receptor 2 (HER2) or Are HER2 Amplified That Did Not Respond or Stopped Responding to Approved Therapies
Status: Completed, Estimated PCD: 2022-01-12
Product
A166
Clinical trial
A Phase II, Randomized, Double-Blind Placebo-Controlled Study of Atezolizumab With or Without Bevacizumab in Combination With Cisplatin Plus Gemcitabine in Patients With Untreated, Advanced Biliary Tract Cancer
Status: Completed, Estimated PCD: 2022-05-16
Clinical trial
A First In Human, Open Label, Dose Escalation Phase I Study Evaluating Safety, Pharmacokinetics, Pharmacodynamics, And Preliminary Clinical Activity Profile Of Single Agent RO7119929 (TLR7 Agonist) Administered Orally To Participants With Unresectable Advanced Or Metastatic Hepatocellular Carcinoma, Biliary Tract Cancer, Or Solid Tumors With Hepatic Metastases
Status: Completed, Estimated PCD: 2023-01-09
Clinical trial
A Randomized, Double-blind, Placebo-controlled, Multicenter Phase III Study to Evaluate the Efficacy and Safety of TQB3454 Tablets in the Treatment of Advanced Biliary Tract Cancer With Isocitrate Dehydrogenase 1 (IDH1) Mutation.
Status: Not yet recruiting, Estimated PCD: 2026-12-01
Product
RO7119929
Product
Tocilizumab
Product
Systemic Treatment
Clinical trial
The Registry of Oncology Outcomes Associated With Testing and Treatment (ROOT)
Status: Recruiting, Estimated PCD: 2029-10-01
Product
TQB3454
Product
TQB3454 tablets
Clinical trial
A Multicentre, Open-label, Single-arm Phase II Study of HA121-28 Tablets in Advanced Biliary Tract Cancer (BTC)
Status: Terminated, Estimated PCD: 2022-12-28
Clinical trial
A Randomized, Open, Parallel, Single Center Phase I Clinical Trial to Evaluate the Effect of Food on the Pharmacokinetics of TQB3454 Tablets in Healthy Adult Subjects.
Status: Not yet recruiting, Estimated PCD: 2023-12-01
Product
HA121-28
Clinical trial
Atezolizumab Plus Tivozanib in Immunologically Cold Tumor Types
Status: Recruiting, Estimated PCD: 2024-12-01
Drug
Atezolizumab
Clinical trial
Camrelizumab Combined With Apatinib and Capecitabine for Patients With Advanced Biliary Tract Cancer: a Phase 2, Single-arm, Prospective Study.
Status: Completed, Estimated PCD: 2023-04-30
Product
Camrelizumab
Drug
apatinib
Clinical trial
DDR-Umbrella Study of DDR (DNA-Damage Response) Targeting Agents in Advanced Biliary Tract Cancer
Status: Active (not recruiting), Estimated PCD: 2024-12-31
Drug
Ceralasertib
Drug
AN0025
Product
Olaparib
Drug
Tivozanib
Clinical trial
Durvalumab Combined With Surufatinib as Maintenance Therapy in Patients With Advanced Biliary Tract Cancer Whose Disease Did Not Progress After Completion of First-line Durvalumab Combined With Gemcitabine+Cisplatin Treatment
Status: Not yet recruiting, Estimated PCD: 2025-10-31
Product
Surufatinib
Clinical trial
An Exploratory Pilot Study of Palliadelic Treatment to Reduce Psychological Distress and Improve Quality of Life in Persons With Pancreatobiliary Cancer, With a Parallel Assessment of Healthcare Utilization and Family Wellbeing
Status: Recruiting, Estimated PCD: 2024-07-01
Product
Psilocybin
Clinical trial
Combination of AZD6738 Plus Durvalumab in Refractory Biliary Tract Cancer in Patients Who Have Failed Immunotherapy
Status: Recruiting, Estimated PCD: 2024-12-31
Clinical trial
Phase II Study Evaluating the Efficacy of M9241 in Combination With Hepatic Artery Infusion Pump (HAIP) and Systemic Therapy for Subjects With Metastatic Colorectal Cancer or Intrahepatic Cholangiocarcinoma
Status: Recruiting, Estimated PCD: 2027-12-31
Drug
FOLFOXIRI
Drug
mFOLFOX6
Product
M9241
Clinical trial
Ambispective Cohort Study of Precision Medicine for Primary Hepatobiliary Cancer Based on Next-generation Sequencing
Status: Recruiting, Estimated PCD: 2025-12-31
Product
Precise Medicine
Clinical trial
Open-label First Line, Single-arm Phase II Study of CisGem Combined With Pembrolizumab in Patients With Advanced or Metastatic Biliary Tract Cancer
Status: Completed, Estimated PCD: 2023-04-27
Drug
Cisplatin
Drug
Gemcitabine
Product
Dexamethasone
Clinical trial
A Phase II Investigator Sponsored Study of Nivolumab in Patients With Advanced Refractory Biliary Tract Cancers
Status: Completed, Estimated PCD: 2019-03-27
Product
Nivolumab
Clinical trial
Two Stage, Multi-center Trial of Candonilimab in Combination With LM-302 for Treatment of Patients With Claudin 18.2 Positive-advanced Biliary Tract Cancer After Failure of Standard of Chemotherapy and PD1/PD-L1 Antibody
Status: Recruiting, Estimated PCD: 2025-08-01
Product
cardonilizumab
Drug
LM-302
Clinical trial
Evaluation of the Efficacy and Safety of Adebrelimab and a TKI in Combination With GEMOX in First-line Treatment of Advanced Biliary Tract Cancers (BTC): a Single-arm, Phase II Clinical Study
Status: Recruiting, Estimated PCD: 2026-02-01
Product
Adebrelimab + GEMOX + TKI
Clinical trial
A Phase II/III Randomized Clinical Trial of CisPlatin plUs Gemcitabine and Nabpaclitaxel (GAP) as pReoperative Chemotherapy Versus Immediate Resection in patIents With resecTable BiliarY Tract Cancers (BTC) at High Risk for Recurrence: PURITY Study
Status: Recruiting, Estimated PCD: 2028-12-01
Product
Nab paclitaxel
Clinical trial
Targeting MDMD and PD1 in Tumors With Tertiary Lymphoid Structures
Status: Not yet recruiting, Estimated PCD: 2026-07-01
Product
Ezabenlimab
Clinical trial
Circulating Tumor DNA Guided Adjuvant Chemotherapy for Biliary Tract Carcinoma: A Prospective Clinical Trial
Status: Not yet recruiting, Estimated PCD: 2025-11-15
Clinical trial
Phase II Trial of Infusional 5 FLUOROURACIL, LEUCOVORIN, OXALIPLATIN AND IRINOTECAN (FOLFIRINOX) in First Line Treatment of Advanced Biliary Tract Cancers
Status: Terminated, Estimated PCD: 2023-02-09
Drug
FOLFIRINOX
Clinical trial
Exploratory Study on the Therapeutic Effect Prediction Model of Immune Checkpoint Inhibitors for Advanced Biliary Tract Cancer
Status: Active (not recruiting), Estimated PCD: 2023-12-30
Product
Immune Checkpoint Inhibitors
Clinical trial
Quantification of 68-GaNOTA-Anti-HER2 VHH1 Uptake in Metastasis of Breast Carcinoma Patients and Assessment of Repeatability (VUBAR) - Pilot Study
Status: Recruiting, Estimated PCD: 2024-11-01
Product
68GaNOTA-Anti-HER2
Clinical trial
Safety of Biliary Intraductal Radiofrequency Ablation in Patients With Unresectable Extrahepatic Biliary Tract Cancer Undergoing Standard of Care Chemo-immune Checkpoint Inhibitor -Therapy: a Phase II, Multicenter, Randomized and Controlled
Status: Not yet recruiting, Estimated PCD: 2026-04-30
Product
Gemcitabin + Cisplatin + Durvalumab
Clinical trial
Phase II Trial of XmAb20717 in Patients With Advanced Biliary Tract Cancers
Status: Active (not recruiting), Estimated PCD: 2024-12-31
Product
XmAb20717
Clinical trial
A Study to Evaluate the Efficacy, Safety, and Immunogenicity of TQB2102 for Injection in the Treatment of HER2-positive Locally Advanced or Metastatic Biliary Tract Cancer
Status: Not yet recruiting, Estimated PCD: 2025-05-01
Product
TQB2102
Clinical trial
A Single Arm Phase 2 Study of Y-90 SIRT in Combination With Durvalumab (MEDI 4736) and Gemcitabine/Cisplatin in Locally Advanced, Unresectable or Metastatic Intrahepatic Cholangiocarcinoma
Status: Recruiting, Estimated PCD: 2026-12-01
Product
Floxuridine
Drug
5-FU
Clinical trial
Hepatic Arterial Infusion Chemotherapy Combined With Adebrelimab and Lenvatinib for Conversion Treatment of Potentially Resectable, Locally Advanced Biliary Tract Cancer: a Single-arm, Exploratory Clinical Study
Status: Not yet recruiting, Estimated PCD: 2027-05-01
Drug
Adebrelimab
Clinical trial
A Single-arm, Single-center, Prospective Clinical Study of the Efficacy and Safety of Chemotherapy Combined With Toripalimab in the Treatment of Advanced Biliary Tract Cancer
Status: Completed, Estimated PCD: 2021-12-01
Product
GS+Toripalimab
Clinical trial
Discovery of Molecular Biomarkers for Predicting Response Through RNA Sequencing in Patients With Advanced Biliary Tract Cancer Who Received Nab-paclitaxel Plus Gemcitabine-cisplatin
Status: Recruiting, Estimated PCD: 2024-03-31
Product
Nab-Paclitaxel + Gemcitabine-Cisplatin
Clinical trial
A Phase I/II Study of CDX-1140, a CD40 Agonist, in Combination With Capecitabine and Oxaliplatin (CAPOX) and Keytruda in Subjects With Biliary Tract Carcinoma (BTC)
Status: Recruiting, Estimated PCD: 2040-06-01
Drug
oxaliplatin
Drug
UTD1
Drug
pembrolizumab
Drug
CDX-1140
Clinical trial
A Phase Ib Adaptive Study Dasatinib for the Prevention of Oxaliplatin-Induced Neuropathy in Patients With Metastatic Gastrointestinal Cancer Receiving FOLFOX Chemotherapy With or Without Bevacizumab
Status: Active (not recruiting), Estimated PCD: 2023-06-22
Product
Dasatinib
Clinical trial
Phase 1 Dose Escalation Trial of ZM008, an Anti-LLT1 Antibody, as Single Agent Followed by Combination With Pembrolizumab in Patients With Advanced Solid Tumors
Status: Recruiting, Estimated PCD: 2026-12-01
Product
ZM008
Clinical trial
Randomized Open-labeled Phase 2 Study of Maintenance Olaparib With or Without Durvalumab for DDR Gene Mutated Advanced Biliary Tract Cancer Following Platinum-based Chemotherapy
Status: Recruiting, Estimated PCD: 2024-12-30
Clinical trial
Brightline-2: A Phase IIa/IIb, Open-label, Single-arm, Multi-centre Trial of Brigimadlin (BI 907828) for Treatment of Patients With Locally Advanced / Metastatic, MDM2 Amplified, TP53 Wild-type Biliary Tract Adenocarcinoma, Pancreatic Ductal Adenocarcinoma, or Other Selected Solid Tumours
Status: Recruiting, Estimated PCD: 2025-06-17
Product
brigimadlin
Clinical trial
A Multi-Center Randomized Phase IB/II Study of Gemcitabine and Cisplatin With or Without CPI-613 as First Line Therapy for Patients With Advanced Unresectable Biliary Tract Cancer (BilT-04)
Status: Active (not recruiting), Estimated PCD: 2024-04-16
Product
CPI 613
Clinical trial
A Phase II, Multicentre, Open-label, Master Protocol to Evaluate the Efficacy and Safety of Datopotamab Deruxtecan (Dato-DXd) as Monotherapy and in Combination With Anticancer Agents in Patients With Advanced/Metastatic Solid Tumours
Status: Recruiting, Estimated PCD: 2026-08-19
Product
Datopotamab deruxtecan
Drug
Saruparib
Clinical trial
Phase II Study of Neoadjuvant Durvalumab (MEDI4736) and Tremelimumab in Combination With Gemcitabine and Cisplatin in Patients With Intrahepatic Cholangiocarcinoma That is Borderline Resectable/Resectable But With High Risk for Recurrence.
Status: Recruiting, Estimated PCD: 2026-11-01
Product
Tremelimumab
Product
Prednisone
Clinical trial
Efficacy and Safety of GemCis Plus Trastuzumab Plus Pembrolizumab in Previously Untreated HER2-positive Biliary Tract Cancer
Status: Recruiting, Estimated PCD: 2026-07-01
Product
SOC plus trastuzumab and pembrolizumab
Clinical trial
Randomized, Double-Blind, Phase 2 Study of Ramucirumab or Merestinib or Placebo Plus Cisplatin and Gemcitabine as First-Line Treatment in Patients With Advanced or Metastatic Biliary Tract Cancer
Status: Active (not recruiting), Estimated PCD: 2018-02-16
Product
Ramucirumab
Product
Merestinib
Clinical trial
Intraperitoneal Aerosolized Nanoliposomal Irinotecan (Nal-IRI) in Peritoneal Carcinomatosis From Gastrointestinal Cancer: a Phase I Study
Status: Recruiting, Estimated PCD: 2025-08-01
Product
PIPAC with Nal-IRI
Clinical trial
A Single Arm Phase Ib/II Multi-Center Study of Nivolumab in Combination With Nanoliposomal-Irinotecan, 5-Fluorouracil, and Leucovorin as Second Line Therapy for Patients With Advanced Biliary Tract Cancer
Status: Active (not recruiting), Estimated PCD: 2025-05-01
Drug
T-VEC
Product
Nanoliposomal-Irinotecan
Clinical trial
A Phase 2 Study to Evaluate the Efficacy and Safety of Adoptive Transfer of Autologous Tumor Infiltrating Lymphocytes in Patients With Locally Advanced, Recurrent, or Metastatic Biliary Tract Cancers
Status: Recruiting, Estimated PCD: 2029-01-31
Product
Tumor Infiltrating Lymphocytes
Clinical trial
Phase II Multi-Center Study of PARP Inhibitor Rucaparib in Combination With Anti-PD-1 Antibody Nivolumab in Patients With Advanced or Metastatic Biliary Tract Cancer Following Platinum Therapy
Status: Active (not recruiting), Estimated PCD: 2023-02-07
Product
Rucaparib
Clinical trial
A Single-arm, Multi-center, Phase II Study of Tislelizumab, Lenvatinib and GEMOX Transformation in the Treatment of Potentially Resectable, Locally Advanced Biliary Tract Cancer
Status: Active (not recruiting), Estimated PCD: 2023-07-03
Product
PD-1+Lenvatinib+GEMOX
Clinical trial
Envolizumab in Combination With Sovalteinib for the Treatment of Treated Bile Duct Cancer in an Open, Single-arm, Phase II Clinical Study
Status: Not yet recruiting, Estimated PCD: 2024-06-30
Product
Envolizumab
Clinical trial
A Phase Ib, Multi-centre, Open-label Study of a First-in-class Nucleotide Analogue Acelarin (NUC-1031) in Combination With Cisplatin in Patients With Locally Advanced/Metastatic Biliary Tract Cancers
Status: Completed, Estimated PCD: 2019-03-01
Product
Acelarin
Clinical trial
A Phase 1/2 Study to Evaluate the Safety and Efficacy of MK-2870 Monotherapy or in Combination With Other Anticancer Agents in Gastrointestinal Cancers
Status: Not yet recruiting, Estimated PCD: 2028-12-03
Product
Sacituzumab tirumotecan
Clinical trial
A Phase III Open-Label, Multi-Centre, Randomized Study Comparing NUC-1031 Plus Cisplatin to Gemcitabine Plus Cisplatin in Patients With Previously Untreated Locally Advanced or Metastatic Biliary Tract Cancer
Status: Terminated, Estimated PCD: 2022-03-02
Product
NUC-1031
Clinical trial
Nal-IRI With 5-fluorouracil (5-FU) and Leucovorin or Gemcitabine Plus Cisplatin in Advanced Biliary-tract Cancer - An Open Label, Non-comparative, Randomized, Multicenter Phase II Trial
Status: Active (not recruiting), Estimated PCD: 2022-01-01
Product
Arm NaI-IRI + 5-FU + Leucovorin
Product
Arm Cisplatin + Gemcitabine
Clinical trial
Study of Gemcitabine, Cisplatin, Quemliclustat (AB680) and Zimberelimab (AB122) During First-line Treatment of Advanced Biliary Tract Cancers (QUIC)
Status: Recruiting, Estimated PCD: 2025-01-01
Product
Zimberelimab
Drug
Quemliclustat
Clinical trial
Phase II Study of Combination of Trametinib (MEK Inhibitor) and Hydroxychloroquine (HCQ) (Autophagy Inhibitor) in Patients With KRAS Mutation Refractory Bile Tract Carcinoma (BTC).
Status: Terminated, Estimated PCD: 2022-05-11
Product
Trametinib
Product
Hydroxychloroquine
Clinical trial
A Pilot Study of Combined Immune Checkpoint Inhibition in Combination With Ablative Therapies in Subjects With Hepatocellular Carcinoma (HCC) or Biliary Tract Carcinomas (BTC)
Status: Completed, Estimated PCD: 2021-02-17
Clinical trial
A Phase Ib/II Single-arm Study Evaluating the Safety and Efficacy of Combined Immunotherapy With mFOLFOX6, Bevacizumab and Atezolizumab in Advanced-stage Biliary Tract Cancer
Status: Recruiting, Estimated PCD: 2024-06-01
Product
mFOLFOX6
Clinical trial
A Study to Evaluate the Efficacy of Propranolol in Boosting Immunotherapy in Hepatocellular Carcinoma, Cholangiocarcinoma and Pancreatic Adenocarcinoma
Status: Not yet recruiting, Estimated PCD: 2025-10-01
Product
Propranolol
Clinical trial
An Open Label Phase II Basket Trial Exploring the Efficacy and Safety of the Combination of Niraparib and Dostarlimab in Patients With DNA Repair-deficient or Platinum-sensitive Solid Tumors
Status: , Estimated PCD: 2024-12-01
Clinical trial
A Single Arm Phase II Study of the Combination of DKN-01 and Nivolumab in Previously Treated Patients With Advanced Biliary Tract Cancer (BTC)
Status: Terminated, Estimated PCD: 2022-09-25
Drug
Trastuzumab
Clinical trial
Adebrelimab With or Without SHR-8068 in Combination With Cisplatin Plus Gemcitabine as First-line Treatment in Patients With Advanced Biliary Tract Cancer: A Randomized, Open-label, Multicenter, Phase II Study
Status: Not yet recruiting, Estimated PCD: 2026-12-30
Product
SHR-8068
Clinical trial
DESTINY-Biliary Tract Cancer-01: A Phase 3 Study of Trastuzumab Deruxtecan (T-DXd) and Rilvegostomig Versus Standard-of-Care Gemcitabine, Cisplatin, and Durvalumab for First Line Locally Advanced or Metastatic HER2-expressing Biliary Tract Cancer
Status: Not yet recruiting, Estimated PCD: 2028-04-26
Clinical trial
A Single-arm, Single-center Study of Durvalumab Combined With S-1 as Adjuvant Therapy for Resectable Biliary Tract Cancer(BTC) With High Risk of Recurrence
Status: Active (not recruiting), Estimated PCD: 2026-12-30